血友病患者的血栓性疾病:这是一个悖论在一个状态的hypocoagulability?
Oana Viola Badulescu1, Minerva Codruta Badescu2, Iris Bararu Bojan1
1Department of Pathophysiology, Morpho-Functional Sciences (II), Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Diagnostics (Basel, Switzerland)
|February 10, 2024
概括
血友病患者通常容易出血,但矛盾的是,他们面临着血栓形成的风险增加. 这种复杂的疾病涉及血友病严重程度,遗传因素和潜在的凝结因子疗法.
科学领域:
- 血液学 血液学 血液学
- 血栓形成的研究研究
- 血友病研究 血友病研究
背景情况:
- 血友病的特点是凝血因子缺乏,导致出血障碍.
- 矛盾的是,血友病患者表现出高血栓事件的风险,如深静脉血栓和肺栓塞.
研究的目的:
- 探索血友病患者血栓形成风险的复杂病理生理学.
- 为了确定导致血友病患者矛盾性血栓事件的因素.
主要方法:
- 关于血友病和血栓形成的现有文献的审查.
- 对血友病队伍中血栓形成风险的因素的分析.
- 研究凝血因子替代疗法的作用.
主要成果:
- 血友病中血栓形成的风险是多因素的,受血友病严重程度和遗传倾向的影响.
- 同时存在的危险因素,如肥胖,吸烟和荷尔蒙疗法加剧了血栓形成的风险.
- 凝血因子替代疗法可能会在某些血友病例中导致血栓形成.
结论:
- 血友病中血栓形成是一个复杂的现象,需要进一步调查.
- 了解这些矛盾的风险对于全面的血友病患者管理至关重要.
- 需要进一步的研究来阐明精确的机制和优化治疗策略.
相关概念视频
Disorders of Hemostasis
911
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
911
Anticoagulant Drugs: Low-Molecular-Weight Heparins
698
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
698
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis
7.7K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
Coagulation
6.6K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.6K
Clot Retraction and Fibrinolysis
5.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.9K


